Fagron Compounding Services recalls bevacizumab (Avastin) Injection
FDA Class II
FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.
- Hazard
- Lack of Assurance of Sterility
- Products
-
- bevacizumab (Avastin) Injection
- Company
- Fagron Compounding Services
- Where it was sold
-
USA nationwide.
Nationwide
- Units affected
- 109,320 syringes
- About this recall
- bevacizumab (Avastin) Injection, 1.25mg/0.05mL (0.12 mL Fill), Sterile Single-Dose Syringe, Fagron Sterile Services, 8710 E 34th St N. Wichita, KS 67226